



```

4641                               XhoI       HindIII                               XhoI       HindIII                               4730
5' -GAAAGGACGA CTCGAGGGAC AAGCTTATCT - 30 bp - ACTCGAGGGA CAGCTTATC TATGTCGGGT-3'
3' -CTTTCCTGCT GAGCTCCCTG TTCGAATAGA ----- TGAGCTCCCT GTTCTGATAG ATACAGCCCA-5'

```

pSingle-tTS-shRNA vector map and shRNA cloning site. Complete digestion of the vector with XhoI and HindIII results in the removal of the nucleotides indicated in gray in the above shRNA cloning site. The XhoI/HindIII digested vector will accept annealed ds shRNA oligonucleotides with the corresponding XhoI and HindIII overhangs.

Description

The pSingle-tTS-shRNA vector expresses the tetracycline-controlled transcriptional suppressor (tTS), which controls expression of an shRNA sequence inserted into the shRNA cloning site. The tTS protein is a fusion of the Tet repressor protein (TetR) and the KRAB-AB silencing domain of the Kid-1 protein (SD^{Kid-1}), a powerful transcriptional suppressor (1, 2). In the *absence* of the inducer doxycycline (Dox, a tetracycline derivative), tTS binds to the *tetO* sequences in the modified Tet-responsive Pol III hybrid promoter ($P_{Tight/U6}$) and blocks expression of the shRNA. As Dox is added to the culture medium, tTS dissociates from $P_{Tight/U6}$ to allow Pol III-mediated transcription of the shRNA, resulting in suppression of the target gene in a highly dose-dependent manner. pSingle-tTS-shRNA also contains a ColE1 origin of replication and an ampicillin resistance gene (Amp^r) for propagation and selection in bacteria, as well as a neomycin resistance gene (Neo^r) for selection of stable transformants in mammalian cells.

Use

After digesting pSingle-tTS-shRNA with HindIII and XhoI, clone an annealed ds oligonucleotide encoding your desired shRNA sequence into the vector. Transfect the recombinant vector into cells and select stable, clonal transformants with G418 to obtain a cell line capable of induced suppression of the shRNA's target gene.

(PR943208; published 27 April 2009)



Clontech

United States/Canada
800.662.2566

Asia Pacific
+1.650.919.7300

Europe
+33.(0)1.3904.6880

Japan
+81.(0)77.543.6116

Clontech Laboratories, Inc.
A Takara Bio Company
1290 Terra Bella Ave.
Mountain View, CA 94043
Technical Support (US)
E-mail: tech@clontech.com
www.clontech.com

Location of Features

- P_{SV40} (DNA fragment containing the SV40 promoter): 8–326
- Neo^r (neomycin resistance gene): 361–1155
- TK polyA⁺ (DNA fragment containing the thymidine kinase polyA signal): 1158–1328
- P_{CMVIE} (human cytomegalovirus immediate early promoter): 1518–2105
- tTS (tetracycline-controlled transcriptional suppressor): 2207–3055
- β -globin polyA⁺ (DNA fragment containing the β -globin polyA signal): 3058–4221
- $P_{Tight/U6}$ (modified Tet-responsive Pol III hybrid promoter): 4313–4650
- ColE1 ori (ColE1 origin of replication): 5139–5782
- Amp^r (Ampicillin resistance gene; β -lactamase): 6789–5930

Sequencing Primer Locations

- Sing-Tet-U6-R: (4999–4967): 5'-GAAGC GGAAG AGCGC CCAAT ACGCA AACCG CCT-3'

Selection of Stable Transfectants

- The neomycin resistance gene (Neo^r) confers resistance to G418 (~400 μ g/ml).

Propagation in *E. coli*

- Suitable host strains: DH5 α , DH10B, and other general purpose strains.
- Selectable marker: plasmid confers resistance to ampicillin (100 μ g/ml) in *E. coli* hosts.
- *E. coli* replication origin: ColE1
- Copy number: high

References

1. Freundlieb S., Schirra-Muller, C. & Bujard, H. (1999) *J. Gene Med.* **1**(1):4–12.
2. Witzgall R., O'Leary, E., Leaf, A., Onaldi, D. & Bonventre, J. (1994) *Proc. Natl. Acad. Sci. USA* **91**(10):4514–4518.

Note: The vector sequence was compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by Clontech. This vector has not been completely sequenced.

Notice to Purchaser

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, *in vitro* diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of Clontech Laboratories, Inc.

Tet-Based Expression Products:

Use of the Tetracycline controllable expression systems (the "Tet Technology") is covered by a series of patents including U.S. Patent Nos. 5,464,758 and 5,814,618, which are proprietary to TET Systems Holding GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. Notwithstanding the above, academic and not-for profit research institutions whose research using the Tet Technology is sponsored by for profit organizations, which shall receive ownership to all data and results stemming from the sponsored research, shall need a commercial license agreement from IP Merchandisers in order to use the Tet Technology. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems Holding GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems Holding GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Clontech is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression system to IP Merchandisers, Inc.

For license information, please contact:

TET Systems Holding GmbH & Co. KG

Attn: CEO

Im Neuenheimer Feld 582

69120 Heidelberg

Germany

Tel +49 6221 588 04 00

Fax +49 6221 588 04 04

eMail: info@tet-systems.com

or use our electronic licensing request form via http://www.tetsystems.com/main_inquiry.htm

Clontech, the Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc., unless noted otherwise.

Clontech is a Takara Bio Company. ©2009 Clontech Laboratories, Inc.